Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
Yasmin M AbazaTapan Mahendra KadiaElias J JabbourMarina Y KonoplevaGautam BorthakurAlessandra FerrajoliZeev EstrovWilliam G WierdaAna AlfonsoToh Han ChongCharles ChuahLiang-Piu KohBoon-Cher GohJulie E ChangDaniel E DurkesMaria Cielo FoudrayHagop M KantarjianXiao Qin DongGuillermo Garcia-ManeroPublished in: Cancer (2017)
The results of the current study demonstrate that pracinostat is safe, with modest single-agent activity in patients with hematological malignancies. Cancer 2017;123:4851-9. © 2017 American Cancer Society.